Zhejiang CONBA Pharmaceutical Co Ltd

SHG:600572 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.53 Billion
CN¥11.26 Billion CNY
Market Cap Rank
#6148 Global
#902 in China
Share Price
CN¥4.44
Change (1 day)
-0.22%
52-Week Range
CN¥4.21 - CN¥4.83
All Time High
CN¥10.42
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nut… Read more

Zhejiang CONBA Pharmaceutical Co Ltd (600572) - Net Assets

Latest net assets as of September 2025: CN¥7.16 Billion CNY

Based on the latest financial reports, Zhejiang CONBA Pharmaceutical Co Ltd (600572) has net assets worth CN¥7.16 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.13 Billion) and total liabilities (CN¥2.97 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥7.16 Billion
% of Total Assets 70.67%
Annual Growth Rate 17.13%
5-Year Change 29.22%
10-Year Change 51.42%
Growth Volatility 30.69

Zhejiang CONBA Pharmaceutical Co Ltd - Net Assets Trend (2001–2024)

This chart illustrates how Zhejiang CONBA Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Zhejiang CONBA Pharmaceutical Co Ltd (2001–2024)

The table below shows the annual net assets of Zhejiang CONBA Pharmaceutical Co Ltd from 2001 to 2024.

Year Net Assets Change
2024-12-31 CN¥6.91 Billion -5.95%
2023-12-31 CN¥7.35 Billion +0.35%
2022-12-31 CN¥7.32 Billion -0.92%
2021-12-31 CN¥7.39 Billion +38.19%
2020-12-31 CN¥5.35 Billion +8.23%
2019-12-31 CN¥4.94 Billion -14.67%
2018-12-31 CN¥5.79 Billion -0.87%
2017-12-31 CN¥5.84 Billion +30.20%
2016-12-31 CN¥4.49 Billion -1.69%
2015-12-31 CN¥4.57 Billion +35.46%
2014-12-31 CN¥3.37 Billion +30.05%
2013-12-31 CN¥2.59 Billion +6.18%
2012-12-31 CN¥2.44 Billion +51.39%
2011-12-31 CN¥1.61 Billion -6.06%
2010-12-31 CN¥1.72 Billion +49.56%
2009-12-31 CN¥1.15 Billion +24.77%
2008-12-31 CN¥919.66 Million +7.59%
2007-12-31 CN¥854.74 Million +36.18%
2006-12-31 CN¥627.66 Million +5.47%
2005-12-31 CN¥595.08 Million +5.31%
2004-12-31 CN¥565.05 Million +135.99%
2003-12-31 CN¥239.44 Million +19.27%
2002-12-31 CN¥200.75 Million +10.37%
2001-12-31 CN¥181.89 Million --

Equity Component Analysis

This analysis shows how different components contribute to Zhejiang CONBA Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 10359.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥3.64 Billion 53.31%
Common Stock CN¥2.58 Billion 37.88%
Other Components CN¥601.35 Million 8.82%
Total Equity CN¥6.82 Billion 100.00%

Zhejiang CONBA Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Zhejiang CONBA Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Bank First National Corp
NASDAQ:BFC
 		$1.37 Billion
IperionX Limited American Depositary Share
NASDAQ:IPX
 		$1.37 Billion
Asker Healthcare Group AB
F:I88
 		$1.37 Billion
Zotye Automobile Co Ltd
SHE:000980
 		$1.37 Billion
HomeCo Daily Needs REIT
PINK:HDNRF
 		$1.37 Billion
China TransInfo Technology Co Ltd
SHE:002373
 		$1.37 Billion
Teijin Limited
F:TIJ
 		$1.37 Billion
Bossard Holding AG
OTCGREY:BHAGF
 		$1.37 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhejiang CONBA Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 7,041,063,708 to 6,819,709,642, a change of -221,354,066 (-3.1%).
  • Net income of 622,417,035 contributed positively to equity growth.
  • Dividend payments of 523,535,776 reduced retained earnings.
  • Share repurchases of 299,987,133 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥622.42 Million +9.13%
Dividends Paid CN¥523.54 Million -7.68%
Share Repurchases CN¥299.99 Million -4.4%
Other Changes CN¥-20.25 Million -0.3%
Total Change CN¥- -3.14%

Book Value vs Market Value Analysis

This analysis compares Zhejiang CONBA Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.62x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 32.75x to 1.62x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 CN¥0.14 CN¥4.44 x
2002-12-31 CN¥0.15 CN¥4.44 x
2003-12-31 CN¥0.18 CN¥4.44 x
2004-12-31 CN¥0.39 CN¥4.44 x
2005-12-31 CN¥0.41 CN¥4.44 x
2006-12-31 CN¥0.38 CN¥4.44 x
2007-12-31 CN¥0.55 CN¥4.44 x
2008-12-31 CN¥0.54 CN¥4.44 x
2009-12-31 CN¥0.60 CN¥4.44 x
2010-12-31 CN¥0.93 CN¥4.44 x
2011-12-31 CN¥0.79 CN¥4.44 x
2012-12-31 CN¥1.21 CN¥4.44 x
2013-12-31 CN¥1.16 CN¥4.44 x
2014-12-31 CN¥1.35 CN¥4.44 x
2015-12-31 CN¥1.79 CN¥4.44 x
2016-12-31 CN¥1.76 CN¥4.44 x
2017-12-31 CN¥2.26 CN¥4.44 x
2018-12-31 CN¥2.15 CN¥4.44 x
2019-12-31 CN¥1.75 CN¥4.44 x
2020-12-31 CN¥2.00 CN¥4.44 x
2021-12-31 CN¥2.75 CN¥4.44 x
2022-12-31 CN¥2.69 CN¥4.44 x
2023-12-31 CN¥2.74 CN¥4.44 x
2024-12-31 CN¥2.74 CN¥4.44 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhejiang CONBA Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 9.13%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 9.55%
  • • Asset Turnover: 0.66x
  • • Equity Multiplier: 1.45x
  • Recent ROE (9.13%) is below the historical average (12.81%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 23.74% 10.94% 0.86x 2.51x CN¥24.50 Million
2002 21.21% 9.49% 0.95x 2.35x CN¥22.11 Million
2003 16.87% 8.55% 0.81x 2.45x CN¥16.32 Million
2004 5.53% 4.75% 0.61x 1.89x CN¥-23.17 Million
2005 8.17% 5.04% 0.75x 2.16x CN¥-9.79 Million
2006 15.00% 6.60% 1.02x 2.23x CN¥28.15 Million
2007 12.54% 8.58% 0.80x 1.83x CN¥21.52 Million
2008 10.09% 8.40% 0.70x 1.72x CN¥857.81K
2009 10.15% 7.20% 0.73x 1.93x CN¥1.49 Million
2010 12.67% 10.31% 0.77x 1.60x CN¥41.07 Million
2011 19.72% 12.40% 0.76x 2.08x CN¥138.15 Million
2012 13.60% 10.82% 0.60x 2.09x CN¥78.26 Million
2013 17.63% 14.27% 0.66x 1.88x CN¥180.61 Million
2014 19.79% 15.42% 0.57x 2.26x CN¥273.30 Million
2015 10.63% 8.31% 0.55x 2.31x CN¥26.22 Million
2016 10.25% 7.33% 0.71x 1.97x CN¥10.61 Million
2017 12.41% 13.43% 0.56x 1.64x CN¥138.22 Million
2018 14.43% 11.62% 0.66x 1.90x CN¥250.17 Million
2019 -7.41% -5.11% 0.69x 2.11x CN¥-811.87 Million
2020 9.02% 7.67% 0.64x 1.85x CN¥-49.32 Million
2021 28.57% 30.72% 0.61x 1.53x CN¥1.31 Billion
2022 5.18% 5.97% 0.55x 1.58x CN¥-333.27 Million
2023 8.40% 8.79% 0.60x 1.60x CN¥-112.53 Million
2024 9.13% 9.55% 0.66x 1.45x CN¥-59.55 Million

Industry Comparison

This section compares Zhejiang CONBA Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Zhejiang CONBA Pharmaceutical Co Ltd (600572) CN¥7.16 Billion 23.74% 0.42x $1.37 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million